TDMS Study 05160-06 Pathology Tables
NTP Experiment-Test: 05160-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1-CHLORO-2-PROPANOL Date: 07/30/97
Route: DOSED WATER Time: 09:05:21
2 YEAR CHRONIC
Facility: TSI Mason Research
Chemical CAS #: 127-00-4
Lock Date: 01/24/94
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05160-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1-CHLORO-2-PROPANOL Date: 07/30/97
Route: DOSED WATER Time: 09:05:21
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 250 PPM 500 PPM 1000 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Natural Death 7 11 10 11
Moribund Sacrifice 8 7 3 5
Accidently Killed 3 1 2
Survivors
Terminal Sacrifice 32 32 36 32
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (50) (50) (50) (50)
Gallbladder (42) (44) (45) (40)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Carcinoma, Metastatic, Urinary Bladder 1 (2%)
Histiocytic Sarcoma 1 (2%)
Intestine Large, Cecum (44) (46) (48) (49)
Intestine Small, Duodenum (43) (46) (46) (47)
Intestine Small, Jejunum (46) (45) (47) (46)
Carcinoma 1 (2%)
Leiomyosarcoma, Metastatic, Uncertain
Primary Site 1 (2%)
Intestine Small, Ileum (46) (44) (45) (45)
Liver (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Carcinoma, Metastatic, Urinary Bladder 1 (2%)
Carcinoma, Metastatic, Intestine Small,
Jejunum 1 (2%)
Fibrous Histiocytoma, Metastatic, Uncertain
Primary Site 1 (2%)
Hemangiosarcoma 1 (2%) 1 (2%) 1 (2%)
Hepatoblastoma 1 (2%) 1 (2%) 1 (2%)
Hepatocellular Carcinoma 6 (12%) 9 (18%) 7 (14%) 9 (18%)
Hepatocellular Carcinoma, Multiple 2 (4%) 1 (2%)
Hepatocellular Adenoma 12 (24%) 12 (24%) 10 (20%) 10 (20%)
Hepatocellular Adenoma, Multiple 28 (56%) 27 (54%) 32 (64%) 30 (60%)
Histiocytic Sarcoma 2 (4%) 1 (2%) 2 (4%)
Leiomyosarcoma, Metastatic, Uncertain
Primary Site 1 (2%)
Lipoma 1 (2%)
Mesentery (20) (19) (16) (12)
Page 2
NTP Experiment-Test: 05160-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1-CHLORO-2-PROPANOL Date: 07/30/97
Route: DOSED WATER Time: 09:05:21
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 250 PPM 500 PPM 1000 PPM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Carcinoma, Metastatic, Uncertain Primary Site 2 (11%)
Carcinoma, Metastatic, Urinary Bladder 1 (6%)
Carcinoma, Metastatic, Intestine Small,
Jejunum 1 (5%)
Hemangioma 1 (5%)
Hemangiosarcoma, Metastatic, Uterus 1 (5%)
Histiocytic Sarcoma 1 (5%) 1 (6%)
Pancreas (50) (50) (50) (50)
Carcinoma, Metastatic, Uncertain Primary Site 2 (4%)
Carcinoma, Metastatic, Urinary Bladder 1 (2%)
Fibrous Histiocytoma, Metastatic, Uncertain
Primary Site 1 (2%)
Histiocytic Sarcoma 1 (2%)
Leiomyosarcoma, Metastatic, Uncertain
Primary Site 1 (2%)
Acinus, Adenoma 1 (2%)
Salivary Glands (50) (50) (49) (50)
Stomach, Forestomach (50) (50) (50) (50)
Carcinoma, Metastatic, Urinary Bladder 1 (2%)
Squamous Cell Papilloma 1 (2%) 1 (2%)
Stomach, Glandular (50) (50) (48) (50)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Carcinoma, Metastatic, Urinary Bladder 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (50)
Adenoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Adrenal Medulla (50) (50) (50) (50)
Pheochromocytoma Malignant 1 (2%)
Islets, Pancreatic (50) (50) (50) (50)
Adenoma 1 (2%)
Pituitary Gland (49) (49) (47) (46)
Pars Distalis, Adenoma 6 (12%) 5 (10%) 3 (6%) 4 (9%)
Pars Intermedia, Adenoma 1 (2%) 1 (2%)
Thyroid Gland (50) (50) (50) (50)
Follicular Cell, Adenoma 1 (2%) 2 (4%) 1 (2%)
Page 3
NTP Experiment-Test: 05160-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1-CHLORO-2-PROPANOL Date: 07/30/97
Route: DOSED WATER Time: 09:05:21
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 250 PPM 500 PPM 1000 PPM
____________________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (3) (1) (2)
Histiocytic Sarcoma 1 (33%)
Leiomyosarcoma, Metastatic, Uncertain
Primary Site 1 (50%)
Pelvic, Hemangiosarcoma 1 (33%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (50) (49) (48) (49)
Histiocytic Sarcoma 1 (2%)
Ovary (50) (49) (50) (50)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Carcinoma, Metastatic, Urinary Bladder 1 (2%)
Cystadenoma 1 (2%) 1 (2%) 2 (4%)
Granulosa Cell Tumor Benign 1 (2%)
Granulosa-Theca Tumor Benign 1 (2%)
Hemangioma 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 2 (4%)
Uterus (50) (50) (50) (50)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 2 (4%)
Polyp Stromal 1 (2%) 2 (4%) 1 (2%)
Sarcoma Stromal 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Lymph Node (8) (12) (15) (9)
Histiocytic Sarcoma 1 (13%)
Deep Cervical, Histiocytic Sarcoma 1 (13%)
Iliac, Hemangiosarcoma 1 (8%)
Iliac, Hemangiosarcoma, Metastatic, Uterus 1 (13%)
Iliac, Histiocytic Sarcoma 2 (25%) 1 (8%)
Inguinal, Histiocytic Sarcoma 1 (13%)
Mediastinal, Histiocytic Sarcoma 1 (13%) 1 (8%)
Pancreatic, Fibrous Histiocytoma, Metastatic,
Uncertain Primary Site 1 (7%)
Pancreatic, Histiocytic Sarcoma 1 (13%)
Renal, Histiocytic Sarcoma 1 (13%) 1 (7%)
Page 4
NTP Experiment-Test: 05160-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1-CHLORO-2-PROPANOL Date: 07/30/97
Route: DOSED WATER Time: 09:05:21
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 250 PPM 500 PPM 1000 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Lymph Node, Mandibular (50) (49) (49) (50)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Carcinoma, Metastatic, Urinary Bladder 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Lymph Node, Mesenteric (49) (48) (47) (49)
Fibrous Histiocytoma, Metastatic, Uncertain
Primary Site 1 (2%)
Hemangioma 1 (2%)
Histiocytic Sarcoma 2 (4%) 1 (2%) 2 (4%)
Leiomyosarcoma, Metastatic, Uncertain
Primary Site 1 (2%)
Spleen (49) (50) (50) (50)
Fibrous Histiocytoma, Metastatic, Uncertain
Primary Site 1 (2%)
Hemangiosarcoma 1 (2%) 2 (4%) 1 (2%) 2 (4%)
Histiocytic Sarcoma 1 (2%)
Thymus (48) (48) (45) (49)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (50) (50)
Subcutaneous Tissue, Fibrosarcoma 1 (2%) 1 (2%) 1 (2%)
Subcutaneous Tissue, Fibrosarcoma, Multiple 1 (2%)
Subcutaneous Tissue, Fibrous Histiocytoma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%) 2 (4%) 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (1) (2)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (50%)
Sarcoma, Metastatic, Skin 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (49) (50) (50)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 5
NTP Experiment-Test: 05160-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1-CHLORO-2-PROPANOL Date: 07/30/97
Route: DOSED WATER Time: 09:05:21
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 250 PPM 500 PPM 1000 PPM
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 4 (8%) 1 (2%) 4 (8%) 4 (8%)
Alveolar/Bronchiolar Carcinoma 5 (10%) 1 (2%) 2 (4%) 3 (6%)
Carcinoma, Metastatic, Harderian Gland 2 (4%) 1 (2%)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%) 1 (2%)
Carcinoma, Metastatic, Urinary Bladder 1 (2%)
Hemangiosarcoma, Metastatic, Uterus 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (4%) 4 (8%) 3 (6%) 1 (2%)
Histiocytic Sarcoma 2 (4%) 1 (2%) 2 (4%)
Nose (50) (50) (50) (50)
Carcinoma, Metastatic, Harderian Gland 1 (2%) 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Trachea (50) (50) (50) (50)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (5) (3) (2) (1)
Adenoma 3 (60%) 1 (33%) 1 (50%)
Carcinoma 2 (40%) 2 (67%) 1 (50%) 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Urinary Bladder (48) (49) (48) (49)
Fibrous Histiocytoma, Metastatic, Uncertain
Primary Site 1 (2%)
Histiocytic Sarcoma 1 (2%)
Transitional Epithelium, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 2 (4%) 1 (2%) 2 (4%)
Lymphoma Malignant 10 (20%) 14 (28%) 10 (20%) 11 (22%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 05160-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1-CHLORO-2-PROPANOL Date: 07/30/97
Route: DOSED WATER Time: 09:05:21
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 250 PPM 500 PPM 1000 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 46 49 46 44
Total Primary Neoplasms 94 95 86 84
Total Animals with Benign Neoplasms 42 43 43 41
Total Benign Neoplasms 60 57 55 52
Total Animals with Malignant Neoplasms 28 30 25 22
Total Malignant Neoplasms 34 38 31 32
Total Animals with Metastatic Neoplasms 8 6 6 3
Total Metastatic Neoplasm 14 17 24 6
Total Animals with Malignant Neoplasms 1 2 2
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 05160-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1-CHLORO-2-PROPANOL Date: 07/30/97
Route: DOSED WATER Time: 09:05:21
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 250 PPM 500 PPM 1000 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 8 7 4
Natural Death 2 6 9 4
Accidently Killed 5 3
Survivors
Terminal Sacrifice 40 44 29 39
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (45) (45) (42) (47)
Adenoma 1 (2%)
Intestine Large, Rectum (50) (50) (50) (50)
Fibrous Histiocytoma, Metastatic, Skin 1 (2%)
Fibrous Histiocytoma, Metastatic, Uncertain
Primary Site 1 (2%)
Intestine Large, Cecum (49) (50) (48) (47)
Intestine Small, Duodenum (49) (49) (47) (47)
Intestine Small, Jejunum (49) (49) (44) (47)
Liver (50) (50) (50) (50)
Fibrous Histiocytoma 1 (2%)
Hemangiosarcoma 2 (4%) 1 (2%) 2 (4%)
Hemangiosarcoma, Multiple 1 (2%) 1 (2%)
Hepatoblastoma 6 (12%) 2 (4%) 6 (12%)
Hepatoblastoma, Multiple 1 (2%)
Hepatocellular Carcinoma 12 (24%) 6 (12%) 5 (10%) 7 (14%)
Hepatocellular Carcinoma, Multiple 1 (2%) 1 (2%) 1 (2%)
Hepatocellular Adenoma 7 (14%) 13 (26%) 21 (42%) 11 (22%)
Hepatocellular Adenoma, Multiple 28 (56%) 22 (44%) 13 (26%) 19 (38%)
Histiocytic Sarcoma 2 (4%) 1 (2%)
Pancreas (50) (50) (50) (50)
Fibrous Histiocytoma 1 (2%)
Fibrous Histiocytoma, Metastatic, Uncertain
Primary Site 1 (2%)
Salivary Glands (50) (50) (50) (50)
Stomach, Forestomach (49) (50) (49) (50)
Squamous Cell Papilloma 1 (2%) 1 (2%) 1 (2%)
Stomach, Glandular (49) (50) (50) (49)
Mast Cell Tumor Benign 1 (2%)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 05160-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1-CHLORO-2-PROPANOL Date: 07/30/97
Route: DOSED WATER Time: 09:05:21
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 250 PPM 500 PPM 1000 PPM
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Fibrous Histiocytoma, Metastatic, Uncertain
Primary Site 1 (2%)
Hemangiosarcoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (50)
Adenoma 1 (2%)
Capsule, Adenoma 1 (2%) 2 (4%) 1 (2%)
Islets, Pancreatic (50) (50) (50) (50)
Adenoma 1 (2%) 2 (4%)
Pituitary Gland (50) (49) (49) (47)
Pars Distalis, Adenoma 1 (2%)
Thyroid Gland (50) (50) (50) (50)
C-Cell, Carcinoma 1 (2%)
Follicular Cell, Adenoma 1 (2%) 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Prostate (50) (50) (49) (50)
Hemangiosarcoma 1 (2%)
Seminal Vesicle (50) (50) (50) (50)
Testes (50) (50) (50) (50)
Interstitial Cell, Adenoma 2 (4%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Hemangiosarcoma 1 (2%) 1 (2%) 1 (2%)
Lymph Node (4) (5) (2) (3)
Fibrous Histiocytoma 1 (20%)
Iliac, Fibrous Histiocytoma 1 (20%)
Mediastinal, Fibrous Histiocytoma 1 (20%)
Pancreatic, Fibrous Histiocytoma 1 (20%)
Renal, Fibrous Histiocytoma 1 (20%) 1 (33%)
Page 9
NTP Experiment-Test: 05160-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1-CHLORO-2-PROPANOL Date: 07/30/97
Route: DOSED WATER Time: 09:05:21
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 250 PPM 500 PPM 1000 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Lymph Node, Mandibular (50) (50) (50) (50)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Fibrous Histiocytoma 1 (2%)
Lymph Node, Mesenteric (49) (50) (50) (50)
Fibrous Histiocytoma 1 (2%)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Spleen (50) (50) (50) (50)
Fibrous Histiocytoma 1 (2%) 1 (2%)
Hemangiosarcoma 1 (2%) 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Thymus (37) (47) (45) (41)
Thymoma Benign 1 (2%)
Thymoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (50) (50)
Subcutaneous Tissue, Fibrous Histiocytoma 1 (2%)
Subcutaneous Tissue, Hemangioma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Osteosarcoma 1 (2%)
Skeletal Muscle (1) (1)
Hemangiosarcoma 1 (100%)
Sarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 11 (22%) 5 (10%) 4 (8%) 4 (8%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 3 (6%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 4 (8%) 2 (4%) 4 (8%) 4 (8%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%) 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Fibrous Histiocytoma 1 (2%)
Page 10
NTP Experiment-Test: 05160-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1-CHLORO-2-PROPANOL Date: 07/30/97
Route: DOSED WATER Time: 09:05:21
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 250 PPM 500 PPM 1000 PPM
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
Hepatoblastoma, Metastatic, Liver 1 (2%) 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 6 (12%) 2 (4%) 1 (2%) 2 (4%)
Histiocytic Sarcoma 1 (2%)
Nose (50) (50) (50) (50)
Carcinoma, Metastatic, Harderian Gland 1 (2%) 1 (2%)
Hemangiosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (1) (5) (3) (1)
Adenoma 1 (100%) 4 (80%) 2 (67%) 1 (100%)
Carcinoma 1 (100%) 1 (20%) 1 (33%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Renal Tubule, Adenoma 1 (2%)
Urinary Bladder (50) (50) (49) (50)
Fibrous Histiocytoma, Metastatic, Uncertain
Primary Site 1 (2%)
Hemangioma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 2 (4%) 1 (2%)
Lymphoma Malignant 1 (2%) 1 (2%) 4 (8%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 11
NTP Experiment-Test: 05160-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1-CHLORO-2-PROPANOL Date: 07/30/97
Route: DOSED WATER Time: 09:05:21
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 250 PPM 500 PPM 1000 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 48 44 40 42
Total Primary Neoplasms 90 80 65 75
Total Animals with Benign Neoplasms 41 39 36 34
Total Benign Neoplasms 53 52 47 43
Total Animals with Malignant Neoplasms 32 17 15 24
Total Malignant Neoplasms 37 28 18 32
Total Animals with Metastatic Neoplasms 8 4 2 3
Total Metastatic Neoplasm 8 7 4 3
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 12
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------